AI
By
Can Standigm’s Knowledge-Graph AI Outperform AI Peers Like Exscientia and Insilico as Global Pharma Commits $500M+ to Collaborative Discovery?
Strategic Overview Standigm is emerging as a distinctive force in AI-driven drug discovery by grounding its platform in…
Is Theremia Using AI to Unlock Next-Generation Immuno-Oncology Therapies and Advance Pharma Partnerships?
Strategic Overview Theremia is emerging as a pioneering AI-driven biotech focused on immune system modulation for oncology, integrating…
Is Karyon Bio Using AI to Decode Disease Networks as Biopharma Moves Beyond Single-Target Drug Discovery?
Strategic Overview Karyon Bio is emerging as a next-generation AI-driven biotech focused on one of the industry’s most…
Is AION Labs Redefining AI Drug Discovery by Incubating Pharma-Native Startups from the Inside Out?
Strategic Overview AION Labs represents a structurally different model in the AI–biopharma landscape: a venture studio co-created by…
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven Small-Molecule Drug Discovery?
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year collaboration valued at…
Pfizer Repositions for Sustainable Growth in 2025 as Core Therapeutic Franchises Reassert Leadership
Pfizer Inc. reported full-year 2025 revenues of $62.6 billion, marking a pivotal year in the company’s post-pandemic transformation.…
